Join Pharvaris for a virtual R&D call, titled “Deucrictibant: Beyond HAE Type 1/2″. The virtual event will explore the pathophysiology and prevalence of bradykinin-mediated angioedema, the current treatment paradigm and unmet needs of those living with bradykinin-mediated angioedema, the potential of deucrictibant to address those unmet needs, and Pharvaris’ biomarker approach to identification of those living with bradykinin-mediated angioedema and other diseases.

Presenters of the event are:

• Danny M. Cohn, MD, PhD – Department of Vascular Medicine, Amsterdam UMC
• Anne Lesage, PhD – Chief Early Development Officer, Pharvaris
• Peng Lu, MD, PhD – Chief Medical Officer, Pharvaris
• Berndt Modig – Chief Executive Officer, Pharvaris

A live question and answer session will follow the formal presentations.